Acurx Pharmaceuticals Inc (NASDAQ: ACXP)’s stock price has increased by 141.62 compared to its previous closing price of 0.31. However, the company has seen a 109.90% increase in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-17 that As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) recurrence through one month after EOT In contrast, 2 of 14 (14%) patients treated with the standard of care, oral vancomycin, experienced recurrent infection within one month after EOT When Phase 2b results are combined with Phase 2a results, 25 of 25 (100%) ibezapolstat-treated patients with CDI who had CC at EOT remained recurrence-free through 1 month after EOT; additionally, all 5 Phase 2b ibezapolstat-treated patients observed for up to 3 months following CC experienced no recurrence of infection Adding to this Lancet Microbe publication, two recent Journal of Antimicrobial Agents and Chemotherapeutics publications regarding, respectively, favorable gut microbiome effects which differentiate IBZ from other anti-CDI antibiotics and positive results from an in-silico study predicting the microbiome-restorative potential of IBZ The totality of ibezapolstat data-to-date further advances Acurx’s robust data package and are reshaping the therapeutic landscape for future treatment of CDI with ibezapolstat’s innovative and potentially transformative new class of antibiotics to treat gram-positive infections while preserving and restoring the protective gut microbiota Acurx is well positioned to begin international Phase 3 clinical trials and has previously been granted FDA QIDP and Fast-Track Designation and has received SME (Small and Medium-sized Enterprise) designation by the EMA STATEN ISLAND, N.Y.
Is It Worth Investing in Acurx Pharmaceuticals Inc (NASDAQ: ACXP) Right Now?
Additionally, the 36-month beta value for ACXP is -1.39. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ACXP is 20.39M and currently, short sellers hold a 1.45% ratio of that float. The average trading volume of ACXP on June 17, 2025 was 182.89K shares.
ACXP’s Market Performance
ACXP stock saw an increase of 109.90% in the past week, with a monthly gain of 91.73% and a quarterly increase of 82.85%. The volatility ratio for the week is 4.03%, and the volatility levels for the last 30 days are 3.53% for Acurx Pharmaceuticals Inc (ACXP). The simple moving average for the last 20 days is 93.28% for ACXP stock, with a simple moving average of -26.31% for the last 200 days.
ACXP Trading at 95.10% from the 50-Day Moving Average
After a stumble in the market that brought ACXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.68% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACXP starting from Scodari Joseph C, who purchase 24,631 shares at the price of $1.01 back on Jan 06 ’25. After this action, Scodari Joseph C now owns 27,708 shares of Acurx Pharmaceuticals Inc, valued at $25,000 using the latest closing price.
Sailer Carl, the Director of Acurx Pharmaceuticals Inc, purchase 24,631 shares at $1.01 during a trade that took place back on Jan 06 ’25, which means that Sailer Carl is holding 137,183 shares at $25,000 based on the most recent closing price.
Stock Fundamentals for ACXP
The total capital return value is set at 0.0. Equity return is now at value -285.79, with -170.68 for asset returns.
Currently, EBITDA for the company is -14.1 million with net debt to EBITDA at 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.93.
Conclusion
In conclusion, Acurx Pharmaceuticals Inc (ACXP) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
